A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.

Trial Details

NCT ID
NCT07027514
Phase
PHASE1
Sponsor
Ankyra Therapeutics, Inc
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • tolododekin alfa
  • Cetrelimab
Locations (sample)
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Buffalo, New York, United States|42.88645,-78.87837
  • New York, New York, United States|40.71427,-74.00597
  • Pinehurst, North Carolina, United States|35.19543,-79.46948

Key Eligibility Criteria

  • Have confirmed locally advanced or metastatic NSCLC
  • Thyroid-stimulating hormone (TSH) within normal limits
  • Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
  • Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →